Biotech
China races to build record biobank to rival US drugs research
Beijing has equally begun to protect its own nascent databases, passing a biosecurity law in 2020
Less than six months after Nasdaq debut, Malaysia’s Alps Group pivots to bridge biotech access gap
It is expanding into insurance and education to rebuild valuation and put advanced treatments within reach for more people
Gilead to buy cancer biotech Tubulis in US$5 billion deal
After the deal closes, Tubulis will become a research arm within Gilead
Now back in the black, SGX-listed Trendlines doubles down on core bets
The group is concentrating on assets in its strongest portfolio companies, says CEO Haim Brosh
US$14.8 million in prepayments to vendors behind Mirxes’ missed 2025 results deadline; independent probe set up
The investigation committee will oversee a review of 14 transactions and ‘associated subsequent events’
Insider and institutional positioning for the week
[SINGAPORE] For the five trading sessions spanning Mar 13 to 19, institutions were net buyers of Singapore stocks, with net institutional inflow of S$365 million. This took the accumulated net inflow ...
Asia’s biotech moment: From regional strength to global impact
Policy reform, new models and cross-border platforms make the region a key driver of biopharma innovation
Human brain cells run new data centres in Singapore, Melbourne
AI is driving a surge in electricity demand, forcing governments and technology companies to search for more efficient computing systems
Nasdaq-listed biotech company Cytek boosts Singapore facility with US$3 million investment
The firm aims to use the site to spearhead growth in Asia-Pacific
AI-powered microalgae hub to anchor Life3 Biotech’s position in sustainable proteins
Facility slated for completion in the fourth quarter of 2026 will house AI-driven bioreactors and a new visitor centre
